OKYO Pharma Ltd (OKYO) - הון עצמי של החברה

OKYO Pharma Limited (OKYO) is fighting for patent leadership by developing drops for neuropathic pain and dry eye, where success depends on OK-101 data. This daily price chart reflects the quotes of the company, which has a market capitalization of 0.01. The biopharmaceutical business in the US and UK focuses on ophthalmological therapy. Currently, the project is funded by investment capital, depleting reserves for trials in the absence of sales.

The assessment of OKYO Pharma Limited (OKYO) margin of safety is based on determining the net asset value minus all liabilities, which allows for the identification of the real value of equity. By analyzing the book capitalization, an investor can compare the market price with the tangible resources of the ophthalmological drug developer, assessing the risk of business undervaluation in the context of creating innovative pain medications.